Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 4 hours ago
- 1 min read
07/05/2026
Incyte announced long-term data from Phase 3 study of ruxolitinib cream in adult patients with AD (Ref)
Incyte announced final 24-week data from its Phase 3, TRuE-AD4 study which evaluated the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs).
The study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 and, IGA-TS.
The majority of patients who achieved EASI50 at Week 8 and continued double-blind, as needed treatment with ruxolitinib cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 and 70.6% achieving IGA-TS.
Treatment with Opzelura was well tolerated.
The data supported a Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union, feedback expected in 1H 2026.
